12 May 2021

Setting a strong foundation for your oral solid dose product to support late-stage development

PDF 2.2 MB

Drug sponsors face significant pressure to reduce the time required to move a new molecule through Phase I and into Phase II trials. If all goes well, identifying the quickest scale-up path for supplying efficacy trials and commercial demands is next. But at early stage, sponsors need to keep the formulation as simple as possible. This means identifying the desired critical quality attributes of a formulation and selecting only those must-have requirements that align closest to the objectives of each clinical trial stage.

Content provided by our supplier

Thermo Fisher Scientific Inc.

  • US
  • 2015
    On CPhI since
  • 5000+

Other Content from Thermo Fisher Scientific Inc.